According to EU-Startups, Adaptam Therapeutics has secured €3 million in pre-seed funding led by Criteria Bio Ventures to develop cancer immunotherapies targeting immunosuppressive myeloid cells. The San Sebastian-based company will use the capital to advance its programs into preclinical development across multiple oncology indications. This financing places Adaptam among several European immuno-oncology ventures securing capital in early 2025, highlighting a strategic shift toward more targeted approaches in cancer treatment.
Table of Contents
Understanding the Myeloid Cell Challenge
The fundamental challenge Adaptam addresses lies in the tumor microenvironment’s complexity, particularly the role of myeloid cells in enabling cancer’s immune evasion. While current immunotherapy approaches have revolutionized cancer treatment by activating T-cells against tumors, they often fail against solid tumors where myeloid cells create protective barriers. These tumor-associated macrophages and other myeloid-derived suppressor cells actively suppress immune responses through multiple mechanisms, creating what essentially functions as an immunological shield around tumors. The scientific understanding of myeloid-mediated immunosuppression has evolved significantly over the past decade, revealing these cells as master regulators of treatment resistance.
Critical Analysis of Adaptam’s Approach
Adaptam’s focus on “glyco-immune checkpoint modulation” represents both innovation and significant risk. While targeting unexplored glycan-binding proteins could yield breakthrough therapies, the glycobiology space remains notoriously challenging for drug development. The structural complexity of glycans and their interactions with immune cells creates substantial hurdles for creating specific, effective therapeutics without off-target effects. Additionally, the company’s dual approach developing both antibody-drug conjugates and bispecific antibodies spreads resources thin at a critical early stage. The transition from academic research at CIC bioGUNE to commercial drug development will test whether the foundational science can withstand the rigorous demands of preclinical validation and eventual clinical testing.
Industry Impact and Competitive Landscape
Adaptam’s funding reflects a broader strategic pivot in cancer immunotherapy investment toward overcoming microenvironment resistance mechanisms. While first-generation checkpoint inhibitors targeted T-cell pathways, the field is now recognizing that myeloid cells represent the next frontier for overcoming treatment resistance. The relatively modest €3 million pre-seed round, while substantial for early-stage European biotech, pales against the €80 million Series A secured by UK-based Trogenix, indicating Adaptam remains in the earliest validation phase. The company’s success will depend on demonstrating clear differentiation from other myeloid-targeting approaches in development, particularly given the crowded landscape of companies targeting tumor-associated macrophages through various mechanisms.
Realistic Outlook and Challenges
The path forward for Adaptam involves substantial technical and financial hurdles. The company’s planned IND-enabling studies represent a critical inflection point where many early-stage biotechs stumble. The transition from academic research to commercially viable therapeutics requires not just scientific excellence but robust manufacturing capabilities and regulatory strategy. Given that the foundational research was published in Nature Communications, the scientific credibility exists, but translating this into clinical candidates will require navigating the notorious “valley of death” between discovery and development. The company’s success will ultimately depend on whether its glyco-immune checkpoint approach can demonstrate clear superiority over existing myeloid-targeting strategies while maintaining acceptable safety profiles—a challenge that has defeated numerous promising approaches in this space.
